Trial Profile
Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-monthly Ibandronate and Once-weekly Risedronate. A Six-month, Two-sequence, and Two-period Crossover Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary) ; Risedronic acid
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Roche
- 19 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by Roche.
- 21 Nov 2006 New trial record.